Reunion Neuroscience Files Lawsuit Against Mindset Pharma
13 März 2023 - 11:52PM
Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or
“the Company”), a clinical-stage biopharmaceutical company
committed to developing innovative and patented therapeutic
solutions for underserved mental health conditions, has filed a
lawsuit today against Mindset Pharma Inc. (“Mindset”) in the United
States District Court for the District of New Jersey, alleging that
Mindset knowingly copied Reunion’s RE104 compound and misleadingly
presented that exact composition to the Patent Office as Mindset’s
invention while applying for U.S. Patent No. 11,591,353 (“‘353
Patent”). Reunion thus seeks to add the original and sole inventor
of Reunion’s RE104 — Dr. Nathan Bryson, Reunion’s Chief Scientific
Officer — as an inventor of the ‘353 Patent. Reunion additionally
asserts claims for, among others, co-ownership of the ‘353 Patent,
inequitable conduct in the prosecution of the ‘353 Patent, and
breach of contract. The complaint can be accessed here.
Reunion is proud of its inventions to further
its mission to improve the lives of patients and families who
suffer from depression and other mental health disorders and
intends to vigorously protect its intellectual property position to
the fullest extent.
About Reunion Neuroscience
Inc.Reunion is committed to developing innovative
therapeutic solutions for underserved mental health conditions. The
Company’s lead asset, RE104, a proprietary, novel, serotonergic
psychedelic compound and the only 4-OH-DiPT prodrug in clinical
development, is being developed as a potential treatment for
postpartum depression that could provide rapid symptom relief and
durable efficacy. RE104 is protected under U.S. Patent No.
11,292,765 issued on April 5, 2022 (priority June 30, 2020), with
claims for composition of matter, methods of manufacturing,
formulations and methods of use for a genus of hemi-ester
tryptamines, including RE104, which could provide protection out to
June 30, 2041. Reunion is also developing the RE200 series, which
includes preclinical compounds with enhanced receptor selectivity
to address additional therapeutic applications.
Learn more at https://www.reunionneuro.com, and follow us
on LinkedIn and Twitter.
To be added to the Reunion Neuroscience email list, please
opt-in at
https://investors.reunionneuro.com/resources/email-alerts.
Cautionary Note Regarding
Forward-Looking Information
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding Reunion and its business.
Often but not always, forward-looking information can be identified
by the use of words such as “expect”, “intends”, “anticipates”,
“plans”, “believes” or variations (including negative variations)
of such words and phrases, or state that certain actions, events or
results “may”, “could”, “would”, “should” or “will” be taken, occur
or be achieved. Such statements are based on the current
expectations and views of future events of the management of
Reunion and are based on assumptions and subject to risks and
uncertainties, many of which are beyond Reunion’s control. Although
the management of Reunion believes that the assumptions underlying
these statements are reasonable, they may prove to be incorrect.
The forward-looking events and circumstances discussed in this
release may not occur and could differ materially as a result of
known and unknown risk factors and uncertainties affecting the
companies, including the funds available to Reunion and the use of
such funds, the assertions and allegations as well as the outcome
and timing of Reunion’s pending litigation versus Mindset Pharma
Inc., the timing, completion and potential outcome of testing and
research on Reunion’s drug trial candidates, RE104 and the RE200
Series, including the ability to recruit patients, to retain and
identify clinical partners, and to optimize dosage amounts, the
likelihood and ability of Reunion to complete an investigational
new drug application and obtain regulatory approvals, as required,
prior to initiating further clinical trials for RE104 and molecules
within the RE200 Series, the ability of Reunion to meet eligibility
requirements for clinical testing and through to more complex
clinical trials, the ability of Reunion to protect and expand its
intellectual property portfolio, the performance of Reunion’s
affiliate, Field Trip Health & Wellness Ltd., the ability of
Reunion to produce and supply its drug trial candidates, market
conditions, economic factors, management’s ability to manage and to
operate the business, the equity markets generally and this and
other Risk Factors disclosed in Reunion’s public filings available
on the SEDAR website at www.sedar.com and on the EDGAR section
of the SEC’s website at www.sec.gov. Although Reunion has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made (or such earlier date, if
identified) and Reunion does not undertake any obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, or otherwise.
Additional information relating to Reunion, including its Annual
Information Form and Risk Factors, can be located on the SEDAR
website at www.sedar.com and on the EDGAR section of the SEC’s
website at www.sec.gov.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange, nor its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Reunion Neuroscience:Greg MayesPresident &
CEO(215) 696-9659gmayes@reunionneuro.com
Media Contact:
Shana
Marino KCSA Strategic Communications(347)
487-6189reunion@kcsa.com
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Reunion Neuroscience (TSX:REUN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024